GH Research PLC (NASDAQ:GHRS) Receives $32.00 Consensus PT from Brokerages

GH Research PLC (NASDAQ:GHRS) has received a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $32.00.

Several equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research note on Friday, May 9th. Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a research note on Saturday, July 5th. JMP Securities reissued a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a report on Tuesday, June 24th. Cantor Fitzgerald began coverage on shares of GH Research in a research report on Wednesday, June 4th. They set an “overweight” rating and a $25.00 target price for the company. Finally, Guggenheim reduced their target price on shares of GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, May 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new stake in shares of GH Research in the fourth quarter worth about $44,000. Palumbo Wealth Management LLC purchased a new position in GH Research during the first quarter valued at approximately $142,000. XTX Topco Ltd bought a new stake in GH Research during the 1st quarter worth approximately $169,000. Two Sigma Investments LP bought a new stake in GH Research during the 4th quarter worth approximately $117,000. Finally, Millennium Management LLC purchased a new stake in GH Research in the 4th quarter worth approximately $145,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $12.15 on Monday. The company has a market capitalization of $632.16 million, a P/E ratio of -15.38 and a beta of 0.98. The company’s 50-day moving average is $13.88 and its 200 day moving average is $11.99. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.42. As a group, research analysts predict that GH Research will post -0.8 earnings per share for the current year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).